You can buy Litfulo at the lowest price in the online pharmacy Nextgen.ooo . Ritlecitinib is a highly selective inhibitor of Janus kinase 3 (JAK3) and a tyrosine kinase expressed by the hepatocellular carcinoma kinase (TEC) family. In June 2023, the FDA approved it for the treatment of severe alopecia areata in adults and adolescents 12 years and older. In September 2023, it was approved by the EMA. Ritlecitinib is administered orally and is the first representative of its class.
 
Ritlecitinib covalently binds to Cys-909 of JAK3, a site where other JAK isoforms have a serine residue. This makes ritlecitinib a highly selective and irreversible inhibitor of JAK3. Other kinases have a cysteine ​​at a position equivalent to Cys-909 in JAK3, and some of these belong to the TEC family of kinases. It has been suggested that the dual activity of ritlecitinib against JAK3 and the TEC family of kinases blocks cytokine signaling as well as cytolytic activity of T cells, which are involved in the pathogenesis of alopecia areata.